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The  effect  of the antioxidant  gallic  acid (GA)  on  Pb toxicity  in  blood,  liver  and kidney  was  investigated  in
the  present  study.  Rats  Wistar  received  Pb  nitrate  (50  mg/Kg/day,  i.p.,  5  days)  followed  by  GA  (13.5 mg/Kg,
p.o.,  3 days)  or a chelating  agent  (EDTA,  55 mg/Kg,  i.p.). As  result,  Pb  decreased  body  weight,  hematocrit
and  blood  -aminolevulinic  acid dehydratase  (ALA-D)  activity.  In  addition,  high  Pb levels  were  observed
in  blood  and  tissues,  together  with  increased  (1)  lipid  peroxidation  in  erythrocytes,  plasma  and  tissues,
(2)  protein  oxidation  in  tissues  and (3) plasma  aspartate  transaminase  (AST)  levels.  These  changes  were
accompanied  by decreasing  in antioxidant  defenses,  like superoxide  dismutase  (SOD)  activity  in  tissues
and  catalase  (CAT)  activity  and  reduced  glutathione  (GSH)  in liver.  GA  was  able  to  reverse  Pb-inducedallic acid
ead
xidative stress
decrease  in  body  weight  and  ALA-D  activity,  as  well  as  Pb-induced  oxidative  damages  and  most  antiox-
idant  alterations,  however  it  did  not  decrease  Pb bioaccumulation  herein  as  EDTA  did.  Furthermore,
EDTA  did  not  show  antioxidant  protection  in  Pb-treated  animals  as GA  did. In  conclusion,  GA decreased
Pb-induced  oxidative  damages  not by decreasing  Pb  bioaccumulation,  but by  improving  antioxidant
defenses,  thus  GA  may  be  promising  in  the  treatment  of  Pb  intoxications.
© 2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. Introduction
Lead (Pb) is a non essential toxic heavy metal and one of the
ost widely used metal in industries. Pb may  be found in printing,
ubber, batteries, ceramics, dye, porcelain manufacturing, in accu-
ulator industry and as a gasoline additive. Especially, the workers
f these industrial branches are exposed to Pb [10,43]. In addition,
he general population may  getting exposed to Pb by contaminated
ood and water and by air pollution caused by industrial emission
∗ Corresponding author at: Universidade de São Paulo, Instituto de Ciências
iomédicas I, Avenida Professor Lineu Prestes 1524, Sala 317 Butantã, São Paulo,
EP 05508-000 SP, Brazil.
E-mail address: reckziegel.patricia@gmail.com (P. Reckziegel).
ttp://dx.doi.org/10.1016/j.toxrep.2016.02.005
214-7500/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
[40,45]. Unfortunately, even small quantities of Pb in the organism
may  are harmful [5,42].
The main body structures affect by Pb exposure includes ery-
throcytes, liver and kidney [46]. The erythrocytes have a high
afﬁnity for Pb and contain about 99% of the Pb present in the blood,
which they can spread to different organs of the body [61]. Liver,
organ responsible for maintaining the body’s metabolic homeosta-
sis, has been considered as the target organ for the toxic effects of
Pb [48] and the largest Pb repository of softy tissues followed by
kidney [28,49]. It has been known that Pb accumulation in these
structures can interfere with several bioelements, whole role is
critical for physiological processes.Actually, Pb toxicity is related with oxidative stress (OS), due
the capacity of Pb in disturbance the oxidant and antioxidant bal-
ance that is found in cells [39]. Lipids, proteins and carbohydrates
can be oxidized by reactive oxygen species (ROS) in OS situa-
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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GFig. 1. Chemical structure of gallic acid (3,4,5-trihydroxybenzoic acid).
ions [24,60]. To minimize the potential damages caused by OS,
he body has a combination of antioxidants [41], which can be
nzymatic [e.g. superoxide dismutase (SOD), catalase (CAT), glu-
athione peroxidase, and glutathione reductase] or non-enzymatic
e.g., non-protein thiol groups, reduzed glutathione (GSH) and vita-
in  C (VIT C) e E] [22]. Several studies had showed increase in
xidative damages parameters, like lipid peroxidation and pro-
ein oxidation, as well as decrease in antioxidant defenses, like
AT, SOD, GSH and ascorbic acid, in blood/tissues of Pb-exposed
nimals [9,13,15,31,32,34,46,53,64]. In these studies, antioxidants
ave been designed to mitigate Pb-induced toxicity.
The current therapeutic approved to Pb intoxications is realized
ith chelation agents [2], like calcium disodium ethylenedi-
mine tetraacetic acid (EDTA), 2,3-dimercaptopropanol (British
nti Lewisite, BAL) or meso 2,3-dimercaptosuccinic acid (DMSA),
hich increase the body excretion of Pb preventing the damages
nduced by this metal. However these compounds have a toxic
otential in themselves [19] and cannot be used at therapeutically
dequate dose for a prolonged period of time [16].
Gallic acid (3,4,5-trihydroxybenzoic acid, GA) (Fig. 1) is a natural
henolic antioxidant extractable from plants, especially green tea
33], and is widely used in foods, drugs, and cosmetics. It received
uch attention because of its antioxidant actions and potent prop-
rty of scavenge ROS, like superoxide anions, hydrogen peroxide,
ydroxyl radicals and hypochlorous acid [52,26,51], attenuating OS.
n our previous study, gallic acid showed protective action against
ocomotor damage and brain OS induced by Pb in rats [53], and
gainst reserpine toxicity [54]. In this sense, the present study
nvestigated the effect of GA in biochemical parameters of toxicity
n blood, liver and kidney of Pb-treated rats.
. Materials and methods
.1. Drugs
Drugs were purchased from Merck (Darmstadt, Germany). Pb
nd EDTA were dissolved in saline and protected from light until
he use time. GA was dissolved in ultra-pure water and used until
0 min  after preparation, thus ensuring its properties. All other
hemicals and solvents used were of analytical or pharmaceutical
nd used as received.
.2. AnimalsThe experiment was conducted with 32 male Wistar rats weigh-
ng 240 ± 10 g (about 2-month-old) at the start of the experiment.
roups of three or four animals were kept in plexiglas cages witheports 3 (2016) 351–356
free access to food and water in a room with controlled tempera-
ture (22–23 ◦C) and in 12 h light/dark cycles with lights on at 7:00
am The number of animals used was the minimum to obtain rele-
vant results. The experimental protocol was approved by the ethical
commission for animal use of Federal University of Santa Maria
(process number 109/2010), which is in accordance with the inter-
national norms of animal care and maintenance. Animals were used
after 7 days of acclimation.
2.3. Experimental design
The animals were treated with saline (1 mL/Kg, i.p., n = 14) or Pb
(50 mg/Kg i.p., n = 21) once a day (9 a.m.) for 5 consecutive days [46].
From day 6, the saline-treated animals received water (1 mL/Kg,
twice a day) or GA (6,75 mg/Kg/mL, twice a day) by gavage for 3 con-
secutive days. In addition, the Pb-treated animals received water
(1 mL/Kg, twice a day, p.o.), GA (6,75 mg/Kg/mL, twice a day, p.o.)
or EDTA (55 mg/Kg/mL, twice a day, i.p.) for 3 consecutive days at 9
a.m. and 5 p.m. Thus, the experimental groups of the present study
were: control (C group, n = 7), GA group (n = 7), Pb group (n = 6), Pb-
GA group (n = 6), Pb-EDTA group (n = 6). GA and EDTA treatments
were in according with methodology described by Reckziegel et al.
[53].
Body weight variation of animals was monitored during the
whole course of the experiment and they were expressed in% based
on the weight recorded on the ﬁrst day. The animals were sacriﬁced
15 h after the last dose under anesthesia with thiopental (50 mg/Kg
body weight, i.p.) and euthanized by exsanguinations. Blood was
collected by cardiac puncture and used to hematocrit and ALA-D
activity and the remaining were centrifuged at 3000 rpm for 15 min
to obtained plasma and erythrocytes, whose were also used for
biochemical assays. The liver and kidney were removed and one
part was stored at −20 ◦C for Pb quantiﬁcation and the remaining
were homogenized in 10 vols (w/v) of 0.1 M Tris-HCl buffer, pH 7.4,
centrifuged at 3000 rpm for 10 min  and the supernatants used for
biochemical assays.
2.4. Biochemical assays
Lipid peroxidation was measured by TBARS levels in tissues [44]
and in plasma and erythrocytes [25,29]. Results of TBARS were
expressed as nmol MDA/g tissue, nmol MDA/mL plasma or nmol
MDA/mL erythrocytes. Protein oxidation was determined by pro-
tein carbonyl levels [65]. Total carbonylation was  calculated using a
molar extinction coefﬁcient of 22,000 M−1 cm−1, according Levine
et al. [30] and the results were expressed as nmol protein car-
bonyl/g tissue. The blood ALA-D activity was  assayed according
to Berlin and Schaller [6] and the results were expressed as nmol
PBG (porphobilinogen)/h/mL blood. Plasma transaminases [alanine
transaminase (ALT) and aspartate transaminase (AST)] were mea-
sured according to Reitman and Frankel [55] and Bessey et al. [8]
and expressed as UI/L.
Antioxidant enzymatic defenses evaluated in the present study
were SOD [38] and CAT [1]. SOD results were expressed as Units
(U)/g tissue (1U = amount of enzyme required to produce 50% inhi-
bition at 40 ◦C) and CAT activity as mol H2O2/min/mL erythrocytes
or mol  H2O2/min/g tissue. In addition, non enzymatic antioxi-
dants measured were GSH levels in tissues and erythrocytes [11,25]
and VIT C levels in plasma [18,25]. The results of GSH levels were
expressed as mol GSH/g tissue or nmol GSH/mL erythrocytes and
of VIT C as g VIT C/mL plasma.
For Pb quantiﬁcation, wet tissue weight and blood volume were
recorded. According to Mesko et al. [36], after sample digestion
with concentrated nitric acid using a microwave-assisted diges-
tion system (Model Multiwave 3000, Anton Paar, Austria), digests
were diluted to a constant volume with ultra pure water (Millipore,
P. Reckziegel et al. / Toxicology R
Table  1
Body weight variation of rats exposed to Pb (50 mg/Kg, i.p., daily) or saline during
5  days and treated with gallic acid (GA, 13.5 mg/Kg, p.o., daily), EDTA (110 mg/Kg,
i.p.,  daily) or water (10 mL/Kg, p.o.) during 3 days.
GROUP Body weight variation (%)
Pb-exposure End
Body weight variation (%)
Treatments End
C +4.1 ± 1.1 +7.9 ± 1.8
GA  +3.8 ± 1.6 +6.0 ± 1.9
Pb  −17.5 ± 1.2** −19.4 ± 2.9**
PbGA −14.8 ± 3.9**, ◦ −12.2 ± 4.1**, #, ◦  ◦
PbEDTA −15.8 ± 1.6** −13.4 ± 2.6**
Body weights in sixth and ninth days were expressed in relation to the initial weight.
Data are expressed as mean ± S.E.M.
** difference from C group (P < 0.001).
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illerica, USA). Determination Pb content was performed follow-
ng the procedure of Peixoto et al. [50] with some modiﬁcations,
sing inductively coupled plasma optical emission spectrometer
ICP OES, Spectro Analytical Instruments, Model Spectro Ciros CCD,
ermany) for tissues and inductively coupled plasma mass spec-
rometer (ICP-MS, PerkinElmer-SCIEX, Model Elan DRC II, Thornhill,
anada) equipped with a concentric nebulizer (Meinhard Asso-
iates, Golden, USA), a bafﬂed cyclonic spray chamber (Glass
xpansion, Inc., West Merbourne, Australia) and a quartz torch with
 quartz injector tube (2 mm i.d.) for blood. The calibration stan-
ards were prepared from a multielemental standard solution by
equential dilution in 5% nitric acid in the range of 0.025–10 g/L.
he Pb detection limit was 0.2 ppm.
.5. Statistical analysis
Data were analyzed by one-way ANOVA, followed by Duncan’s
ultiple range test when appropriate. Probability less than 0.05
ere considered as statistically signiﬁcant. Values were expressed
s mean ± S.E.M.
. Results
The effects of Pb exposure and GA and EDTA treatments on the
ariation (gain/loss) of body weight are show in Table 1. Pb expo-
ure decreased the body weight when compared to control group
n sixth (end Pb exposure) and ninth (end treatment) days of proto-
ol [F(4,30) = 52.87 and F(4,30) = 30.00, respectively; P < 0.001]. The
A, but no EDTA, was able to reverse partially this alteration in the
inth day.
The results of Pb exposure and GA and EDTA treatments on hema-
ocrit levels and ALA-D activity are show in Table 2. It was observed
 decrease in hematocrit levels (9.6%) in Pb exposed animals in
elation to the controls; and this effect was not reversed by any
reatment employed (GA or EDTA) [F(4,30) = 7.26; P < 0.001]. Pb
xposure also decreased blood ALA-D activity in relation to con-
rol group (5 times). GA alone had no effects on this variable, but
he co-treatments Pb plus GA and Pb plus EDTA partially reversed
he effects of Pb on the ALA-D activity. Comparing these two  treat-
ents, EDTA reversed the ALA-D activity more effectively than GA
id, whose values differed signiﬁcantly [F(4,30) = 76.35; P < 0.001].
The results of Pb exposure and GA and EDTA treatments in blood,
iver and kidney oxidative stress parameters and liver damage param-
ters are show in Table 3. Pb exposure increased TBARS levels
n erythrocytes (48.6%) and plasma (42.7%) when compared to
he control group [F(4,30) = 8.11 and F(3,30) = 12.53, respectively,
 < 0.001]. These effects were completely reversed by the treat-
ent with GA. The EDTA treatment partially reversed the TBARS
rythrocytes levels in erythrocytes, but no changed plasma TBARSeports 3 (2016) 351–356 353
levels in relation to Pb group. In tissues, Pb exposure also increased
TBARS levels (35.2% in liver and 47.1% in kidney) in relation to the
control group; GA and EDTA treatments reverted its partially in
liver and completely in kidney [F(3,30) = 11.13 and F(3,30) = 15.78,
respectively; P < 0.001].
Pb exposure increased carbonyl levels in liver (54.4%) and
kidney (65.8%) in relation to control group [F(3,30) = 8.50 and
F(3,30) = 14.22, respectively; P < 0.001]. GA was able to reverse com-
pletely these alterations, but EDTA just partially in kidney and no
in liver.
In  addition, an increase of AST levels in Pb exposed animals
in relation to control group was observed (27.1%) [F(3,30) = 24.36,
P < 0.001]. This effect was  partially reverted by GA and EDTA treat-
ments. No alterations were found in ALT levels.
The results of Pb exposure and GA and EDTA treatments in antiox-
idant parameters are show in Table 4. SOD activity was decreased
in liver and kidney of Pb exposed animals in relation to the control
group (18.5% and 40%, respectively) and these events were par-
tially reverted in liver by GA and EDTA treatments and completely
in kidney just by GA treatment.
It was observed changes in erythrocyte CAT activity just in Pb
exposed animals treated with GA (PbGA group) in relation to con-
trol group (increase of 19.9%) [F(3,30) = 3.11, P < 0.05). In liver, CAT
activity decreased in Pb-exposed animals in relation to control
group (24.3%), and this effect was  completely reversed by GA treat-
ment [F(3,30) = 3.40, P < 0.05]. No changes were observed in kidney
CAT activity.
GSH levels were decreased in liver of Pb exposed animals in
relation to control group (41.5%) [F(3,30) = 7.65, P < 0.001]. GA treat-
ment reversed completely this effect and EDTA treatment, partially.
No changes were observed in erythrocytes and kidney GSH levels,
as well as in plasma VIT C levels.
The effects of Pb exposure and GA and EDTA treatments in Pb lev-
els are show in Table 5. It was  observed an increase in Pb levels
in blood, liver and kidney [F(4,20) = 2.91, P < 0.05; F(4,20) = 3.55,
P < 0.05 and F(4,20) = 68.53, P < 0.001; respectively] in Pb-exposed
animals in relation to control group. This effect was reverted by
EDTA treatment and not by GA treatment.
Statistical analyses revealed a signiﬁcant correlation between
ALA-D activity and blood Pb levels and hematocrit levels (r = 0.57,
P < 0.001 and r = 0.55, P < 0.001, respectively).
4. Discussion
This study showed that rats treated with Pb decrease the body
weight in relation to control animals. This result is in agreement
with several studies [7,12,23,37,57,64], which suggested that less
body weight was  due to reduced food consumption via Pb effects on
the satiety set-point. After the treatment time, only the animals that
received GA showed reversion partial of this less body weight, due
probably the improvement of behavior and biochemical parame-
ters.
Anemia observed in this study in Pb-exposed animals by
decrease in hematocrit can be result by Pb property of inhibit
many stages in the heme synthesis, while, for example, the enzyme
-aminolevulinic acid dehydratase (ALA-D). ALA-D catalyses the
formation of porphobilinogen from -aminolevulinic acid (ALA)
[20] and it is used as one of the most reliable indicators of Pb intox-
ication [35,47]. In the present study, this enzyme was  reduced in
Pb-treated animals, as well as showed negative correlation to Pb
blood levels and positive correlation to hematocrit, proving the
involving between Pb, ALA-D and hematocrit. However, the GA and
EDTA treatments reverted partially the ALA-D inhibition but not
restored hematocrit levels, probably because the Pb also shorten-
ing of erythrocyte life span due the direct toxic effect of Pb upon the
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Table 2
Hematocrit and ALA-D activity of rats exposed to Pb (50 mg/Kg, i.p., daily) or saline during 5 days and treated with gallic acid (GA, 13.5 mg/Kg, p.o., daily), EDTA (110 mg/Kg,
i.p.,  daily) or water (10 mL/Kg, p.o.) during 3 days.
GROUP C GA Pb PbGA PbEDTA
Hematocrit 41.5 ± 0.8 41.2 ± 0.6 37.5 ± 1.6* 36.0 ± 0.3**, ◦ 37.6 ± 0.6*
ALA-D 543.3 ± 24.9 568.3 ± 26.9 107.8 ± 6.6** 303.8 ± 7.0**, - , +, ◦ 301.7 ± 26.3**, #
ALA-D activity (nmol PBG/h/mL blood). Data are expressed as mean ± S.E.M.
* difference from C group (P < 0.05).
** difference from C group (P < 0.001).
# difference from Pb group (P < 0.05).
- difference from Pb group (P < 0.001).
+ difference from PbEDTA group (P < 0.05).
◦ difference from GA group (P < 0.05).
Table 3
Oxidative stress parameters in blood, liver and kidney and plasma aminotransferases of rats exposed to Pb (50 mg/Kg, i.p., daily) or saline during 5 days and treated with
gallic  acid (GA, 13.5 mg/Kg, p.o., daily), EDTA (110 mg/Kg, i.p., daily) or water (10 mL/Kg, p.o.) during 3 days.
GROUP C GA Pb PbGA PbEDTA
TBARS Erythrocytes 17.88 ± 0.77 19.25 ± 1.69 26.57 ± 1.68** 17.05 ± 1.03-, + 22.23 ± 1.20*, #
Plasma 12.42 ± 0.51 13.61 ± 0.68 17.73 ± 0.37** 12.84 ± 0.75-, ++ 17.45 ± 1.10**
Liver 18.6 ± 0.8 18.1 ± 1.1 25.2 ± 1.2* 13.8 ± 1.0*, - 13.8 ± 2.3*, -
Kidney 25.7 ± 0.9 22.6 ± 0.6 37.8 ± 1.7** 28.7 ± 1.9- 24.9 ± 2.0-
CARBONYL Liver 2042.6 ± 235.7 2247.8 ± 115.0 3153.1 ± 191.4** 1862.3 ± 150.1-, + 2798.2 ± 184.8*
Kidney 2209.3 ± 98.6 2020.7 ± 178.3 3664.7 ± 533.9** 1770.9 ± 95.8- 1432.7 ± 170.3*, -
AST Plasma 21.4 ± 0.4 21.5 ± 0.4 27.2 ± 0.6** 25.5 ± 0.2**, #, ◦ 24.3 ± 0.7**, -
ALT Plasma 19.2 ± 0.5 19.6 ± 0.3 18.2 ± 0.4 18.1 ± 0.5 18.4 ± 0.3
TBARS levels (nmol MDA/g tissue); protein carbonyl levels (nmol protein carbonyl/g tissue). Data are expressed as mean ± S.E.M.
* difference from C group (P < 0.05).
** difference from C group (P < 0.001).
# difference from Pb group (P < 0.05).
- difference from Pb group (P < 0.001).
+ difference from PbEDTA group (P < 0.05).
++ difference from PbEDTA group (P < 0.001).
◦ difference from GA group (P < 0.05).
Table 4
Antioxidant parameters in blood, liver and kidney of rats exposed to Pb (50 mg/Kg, i.p., daily) or saline during 5 days and treated with gallic acid (GA, 13.5 mg/Kg, p.o., daily),
EDTA  (110 mg/Kg, i.p., daily) or water (10 mL/Kg, p.o.) during 3 days.
GROUP C GA Pb PbGA PbEDTA
SOD Liver 2.7 ± 0.1 2.8 ± 0.1 2.2 ± 0.1* 2.5 ± 0.1 2.4 ± 0.2
Kidney  1.4 ± 0.1 1.5 ± 0.1 1.0 ± 0.1* 1.4 ± 0.1# 1.3 ± 0.1
CAT  Erythrocyte 26.1 ± 1.0 28.9 ± 1.3 24.4 ± 1.2 31.3 ± 0.9*,- 28.2 ± 2.4
Liver  3017.4 ± 178.3 2917.8 ± 87.3 2284.0 ± 202.8* 2837.4 ± 222.1# 2470.3 ± 137.5*
Kidney 1354.0 ± 39.7 1349.4 ± 15.5 1475.4 ± 90.7 1518.5 ± 22.7 1468.9 ± 61.3
GSH  Erythrocyte 2664.5 ± 121.5 2687.1 ± 124.5 2913.0 ± 44.2 2547.9 ± 67.8 2844.6 ± 209.5
Liver  8.9 ± 0.4 8.8 ± 0.6 5.2 ± 0.8** 8.4 ± 0.5- 6.9 ± 0.3*, #
Kidney 4.3 ± 0.3 3.8 ± 0.4 3.9 ± 0.4 3.2 ± 0.5 4.4 ± 0.8
VIT.  C Plasma 19.3 ± 0.4 19.3 ± 1.1 19.2 ± 2.1 22.4 ± 0.5 21.7 ± 1.6
SOD activity (U/g of tissue); CAT activity (mol  H2O2/min/mL erythrocytes or mol H2O2/min/g tissue); GSH levels (nmol GSH/mL erythrocytes or mmol GSH/g tissue);
plasma  VIT C levels (mg  VIT C/mL plasma). Data are expressed as mean ± S.E.M.
* difference from C group (P < 0.05).
** difference from C group (P < 0.001).
# difference from Pb group (P < 0.05).
- difference from Pb group (P < 0.001).
Table 5
Blood, liver and kidney Pb levels of rats exposed to Pb (50 mg/Kg, i.p., daily) or saline during 5 days and treated with gallic acid (GA, 13.5 mg/Kg, p.o., daily), EDTA (110 mg/Kg,
i.p.,  daily) or water (10 mL/Kg, p.o.) during 3 days.
GROUP C GA Pb PbGA PbEDTA
Blood Pb 0.03 ± 0.00 0.02 ± 0.00 2.98 ± 1.54* 2.69 ± 0.77* 0.82 ± 0.28
Liver  Pb ND ND 129.66 ± 48.85* 149.22 ± 57.72*, ◦ 89.42 ± 36.56
Kidney  Pb ND ND 135.60 ± 11.56** 161.50 ± 16.94**, ++ 37.14 ± 3.17*, -
Lead levels (ppm). ND (no detectable, levels below 0.2 ppm). Data are expressed as mean ± S.E.M.
* difference from C group (P < 0.05).
** difference from C group (P < 0.001).
- difference from Pb group (P < 0.001).
++ difference from PbEDTA group (P < 0.001).
◦ difference from GA group (P < 0.05).
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ell membrane [27] and is required about 3 months for regeneration
f circulating erythrocytes.
OS has been involved in Pb toxicity [17,39]. According, the Pb
ay  cause OS by two separate, although related, pathways: (1) the
eneration of ROS, including hydroperoxides, singlet oxygen, and
ydrogen peroxide, and (2) the depletion of antioxidant reserves
14]. These events were observed in the present study.
The increase in ROS generation can be induced by Pb at different
evels: (i) the Pb-induced inhibition of ALA-D may  lead to accumu-
ation of its substrate ALA, which can oxidize, and (ii) Pb per se
as the capacity to stimulate ferrous ion [3,4,21]. In the present
tudy, the oxidative damages caused by ROS can be observed by
he increase in lipid peroxidation (TBARS levels) in erythrocytes,
lasma, liver and kidney and protein oxidation (carbonyl levels) in
iver and kidney in Pb-exposed animals, conﬁrming previous stud-
es [9,56,58,59,64]. Moreover, Pande et al. [46] did the same our
b treatment protocol and observed increase in lipid peroxidation
n liver. Whereas, GA markedly reversed Pb-induced OS damages,
nd EDTA too, but EDTA was less effective than GA. Reckziegel et al.
53] observed similar results in brain of rats treated with Pb and GA.
urthermore, aminotransferases (AST and ALT) represent enzymes
hat are regarded as markers of liver injury. In this study it was
bserved a modest increase in plasma AST levels, besides it is not
iologically signiﬁcant for liver injury, which was partially reverted
y GA and EDTA treatments.
The antioxidant potential of the body can be enzymatic and non-
nzymatic. The antioxidant enzymes evaluated, SOD and CAT, form
he ﬁrst line of defense against ROS and the decrease in their activ-
ties contribute to the OS [5]. Pb reduced the activity of SOD in liver
nd kidney and of CAT in liver. Interestingly, GA could markedly
enew the activities of these antioxidant enzymes of Pb-exposed
ats and signiﬁcantly enhanced the antioxidant capacity of the
ody. In erythrocytes, GA increased the CAT activity probably as
 compensatory mechanism to eliminate hydroperoxides produce
uring Pb exposure.
GSH is a tripeptide containing cysteine that has a reactive thiol
roup with reductive potency and can act as a non-enzymatic
ntioxidant by direct interaction of thiol group with ROS. Pb binds
xclusively to the thiol groups which decrease the GSH levels
hereby interfering with the antioxidant activity [62]. In this study,
SH levels decreased in liver only and the treatment with GA
everted completely this decrease and with EDTA, partially. It was
bserved that liver was the tissue with antioxidant potential most
ffected by Pb, probably by its involvement in Pb detoxiﬁcation.
urprisingly, other non-enzymatic antioxidant evaluated, the VIT
, a low molecular mass antioxidant that scavenges the aqueous
ree radicals, no change in plasma.
Certainly the higher concentration of Pb in blood and tissues,
ollowing experimental exposure, was associated with increased
xidative reaction, which might be responsible, at least in part,
or Pb-induced toxic effects. In the present study, it was observed
n increase in Pb concentrations in blood, liver and kidney in Pb-
xposed animals in relation to the control ones. We  observed that
DTA, a conventional chelating agent which is used in Pb poison-
ngs, was able to reverse the high Pb concentrations in all structures
valuated, proving it chelating property. In according, Patra et al.
48] found a signiﬁcant higher level of Pb in liver of rats exposed to
b for 4 weeks and a signiﬁcant reduction of Pb levels after treat-
ent with EDTA during ﬁfth week. However, besides its proved
helating property, we observed that EDTA cannot reverse effec-
ively the antioxidants parameters changed by Pb (SOD and CAT
ctivities and GSH levels). In this sense, we believed that EDTA
xidative protection, observed in TBARS and carbonyl levels, can be
ue the chelating action, which decrease Pb body concentrations.
n the other hand, GA no decreased body Pb concentrations, but
everted oxidative parameters and antioxidants alterations. This
[
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results show that GA reversion in oxidative damages induced by Pb
cannot be attributed by chelating property while EDTA, but to its
antioxidant potential and capacity of improve the body antioxidant
defenses.
Data from literature showed that GA  antioxidant property
proven here is due its capacity to scavenge ROS, like superoxide
anions, hydrogen peroxide, hydroxyl radicals and hypochlorous
acid [26,51]. Its molecular structure has tri-hydroxyl groups,
thereby verifying a previous report that phenolic hydroxyl groups
are important in showing a potent radical scavenging effect [63].
Lu et al. [33] showed that the hydroxyl group at the para position
to the carboxylic group is especially effectual for GA antioxidant
activity (Fig. 1).
5. Conclusion
GA is able to reverse oxidative damages induced by Pb due it
antioxidant potential and capacity of improve body antioxidant sta-
tus and not by chelating property. In addition, the results showed
here conﬁrm the beneﬁcial of antioxidants use in Pb intoxications.
Further studies are needed to evaluate the use of GA together of a
chelating agent in Pb-treated rats.
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